Macrocyclic peptide therapeutics
for safer targeted medicine
Macrocyclic peptide therapeutics
for safer targeted medicine
Macrocyclic peptide therapeutics
for safer targeted medicine
Dysruptx is developing precision therapeutics designed to treat human disease while reducing off-target toxicity through a targeted and selective approach.
Dysruptx is developing precision therapeutics designed to treat human disease while reducing off-target toxicity through a targeted and selective approach.
Dysruptx is developing precision therapeutics designed to treat human disease while reducing off-target toxicity through a targeted and selective approach.
Naturally precise by design
Naturally precise by design
Naturally precise by design
Naturally precise by design
Protein–protein interactions have evolved over millions of years to achieve remarkable specificity within complex biological systems.
Protein–protein interactions have evolved over millions of years to achieve remarkable specificity within complex biological systems.
Mapping the interface
Mapping the interface
Mapping the interface
Mapping the interface
Dysruptx starts with these naturally evolved interaction sites to identify highly relevant binding patterns from the outset.
Dysruptx starts with these naturally evolved interaction sites to identify highly relevant binding patterns from the outset.
Designing Dysruptors
Designing Dysruptors
Designing Dysruptors
Designing Dysruptors
From this interface knowledge, Dysruptx develops macrocyclic peptide Dysruptors engineered to mimic and disrupt disease-relevant interactions with precision.
From this interface knowledge, Dysruptx develops macrocyclic peptide Dysruptors engineered to mimic and disrupt disease-relevant interactions with precision.
Selectivity from the start
Selectivity from the start
Selectivity from the start
Selectivity from the start
By addressing off-target toxicity early in discovery, Dysruptx supports a more selective and potentially safer path for targeted therapeutic development.
By addressing off-target toxicity early in discovery, Dysruptx supports a more selective and potentially safer path for targeted therapeutic development.
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
IT'S FREE
Connect with us
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
IT'S FREE
Connect with us
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
IT'S FREE
Connect with us
Who we are
About Dysruptx
About Dysruptx
Dysruptx is a Glasgow-based biotechnology company developing precision macrocyclic peptide therapeutics designed to reduce off-target toxicity and improve the safety of targeted medicines.
Dysruptx is a Glasgow-based biotechnology company developing precision macrocyclic peptide therapeutics designed to reduce off-target toxicity and improve the safety of targeted medicines.
Focus areas
Focus areas
Oncology, inflammation, immunology
Oncology, inflammation, immunology
Selective binding
Protein targeting
Selective binding
Protein targeting
A more precise approach to therapeutic discovery
Focused on improving selectivity and reducing off-target toxicity from the earliest stages.
Precision-led
Designing therapeutics with selectivity built in from the start
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Early risk reduction
Addressing off-target toxicity at the discovery stage, not later
Platform-enabled
Combining therapeutic development with scalable partnership opportunities
A more precise approach to therapeutic discovery
Focused on improving selectivity and reducing off-target toxicity from the earliest stages.
Precision-led
Designing therapeutics with selectivity built in from the start
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Early risk reduction
Addressing off-target toxicity at the discovery stage, not later
Platform-enabled
Combining therapeutic development with scalable partnership opportunities
A more precise approach to therapeutic discovery
Focused on improving selectivity and reducing off-target toxicity from the earliest stages.
Precision-led
Designing therapeutics with selectivity built in from the start
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Early risk reduction
Addressing off-target toxicity at the discovery stage, not later
Platform-enabled
Combining therapeutic development with scalable partnership opportunities